Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD 20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL)

Authors

Yaya Chu, New York Medical CollegeFollow
Meijuan Tian
Mario Q. Marcondes
W Overwijk
Dean Anthony LeeFollow
Christian KleinFollow
Mitchell S. Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

10-2022

Journal Title

Leukemia Research

Department

Pediatrics

Recommended Citation

Chu, Y., Tian, M., Marcondes, M. Q., Overwijk, W., Lee, D. A., Klein, C., & Cairo, M. S. (2022). Optimizing Chimeric Antigen Receptor (CAR) Engineered NK Cell-Mediated Cytotoxicity Combined with Anti-CD 20 or Anti-CD79 Therapeutic Antibodies and NKTR-255 in Burkitt Lymphoma (BL). Leukemia Research, 121 (Suppl.), S27. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/770